Buy CJC-1295 With DAC 2mg Research Peptide OnlineCJC-1295 With DAC Peptide IdentificationCJC-1295 with Drug Affinity Complex (DAC) is a 30-amino-acid synthetic growth hormone-releasing hormone (GHRH) analog incorporating dipeptidyl peptidase-IV (DPP-IV) resistance modifications and a covalent albumin-binding moiety. The DAC component extends preclinical half-life through serum albumin association, enabling sustained receptor signaling investigation in animal and cell-based models. Supplied as lyophilized powder in 2mg vials for long-duration GH axis research protocols.CJC-1295 With DAC Mechanism of ActionIn tissue culture and animal models, CJC-1295 activates GHRH receptor 1a signaling, stimulating growth hormone-releasing hormone receptor-mediated cyclic AMP cascade activation in somatotroph cell lines. The DAC modification prolongs receptor engagement duration by maintaining elevated peptide concentrations through covalent albumin binding, enabling investigation of sustained versus pulsatile GH axis signaling dynamics in controlled preclinical systems and isolated cell preparations.CJC-1295 With DAC Published Research SummaryTeichman et al. (2006, Journal of Clinical Endocrinology & Metabolism) characterized CJC-1295 GHRH receptor pharmacology and DPP-IV resistance mechanisms in controlled preclinical settings. Additional studies document extended half-life profiles in animal models and enhanced GH secretion patterns in research paradigms. Preclinical literature demonstrates DAC modification effectiveness in extending bioavailability duration relevant to long-acting peptide analog research.CJC-1295 With DAC 2mg Product Specifications & HandlingForm: Lyophilized powder, white; Quantity: 2mg per vial; Storage: -20°C, desiccated, sealed; Reconstitution: Sterile saline or bacteriostatic water; Stability: 36 months from manufacture; Purity: >99% by analytical HPLC; Molecular weight: approximately 3.5 kDa (with DAC moiety).CJC-1295 With DAC Research Use Only DisclaimerResearch use only. Not for human consumption, medical use, clinical application, disease treatment, or therapeutic claims. All described mechanisms are based on controlled preclinical research. Institutional review and regulatory approval required for all laboratory use.
